Loxiglumide (CR-1505) (Synonyms: CR1505) |
Catalog No.GC31382 |
Loxiglumide (CR-1505) is a cholecystokinin (CCK-1) receptor antagonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 107097-80-3
Sample solution is provided at 25 µL, 10mM.
Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.
The effects of pancreatic rest by oral administration of CCK-1 receptor antagonist Loxiglumide and pancreas stimulation are investigated via endogenous CCK release induced by po protease inhibitor camostat on the recovery of pancreatic secretory function, and biochemical and histological changes of the pancreas after acute hemorrhagic pancreatitis. Oral administration of CCK-1 receptor antagonist Loxiglumide with a dose of 50 mg/kg body weight inhibits pancreatic exocrine secretion for more than 12 h. Thus, every 12-h administration of Loxiglumide might have completely blocks the effect of endogenously released CCK on the pancreas (pancreatic rest)[1].
[1]. Jia D, et al. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats. World J Gastroenterol. 2015 Jul 7;21(25):7742-53.
Average Rating: 5
(Based on Reviews and 36 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *